$136.11
4.09% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US64125C1099
Symbol
NBIX

Neurocrine Biosciences, Inc. Stock price

$136.11
+8.07 6.30% 1M
+21.63 18.89% 6M
-0.39 0.29% YTD
+11.01 8.80% 1Y
+33.10 32.13% 3Y
+25.34 22.88% 5Y
+88.02 183.03% 10Y
+90.22 196.60% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
-5.81 4.09%

Key metrics

Basic
Market capitalization
$13.5b
Enterprise Value
$12.5b
Net debt
positive
Cash
$975.6m
Shares outstanding
99.0m
Valuation (TTM | estimate)
P/E
39.6 | 30.1
P/S
5.4 | 4.8
EV/Sales
5.0 | 4.4
EV/FCF
23.7
P/B
5.0
Financial Health
Equity Ratio
69.6%
Return on Equity
13.2%
ROCE
14.9%
ROIC
12.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$2.5b | $2.8b
EBITDA
$527.6m | $653.2m
EBIT
$499.1m | $623.7m
Net Income
$348.3m | $447.3m
Free Cash Flow
$528.7m
Growth (TTM | estimate)
Revenue
18.4% | 20.7%
EBITDA
-7.3% | 7.1%
EBIT
-8.4% | 7.0%
Net Income
2.7% | 31.1%
Free Cash Flow
6.9%
Margin (TTM | estimate)
Gross
98.5%
EBITDA
21.0% | 23.0%
EBIT
19.9%
Net
13.9% | 15.7%
Free Cash Flow
21.1%
More
EPS
$3.4
FCF per Share
$5.3
Short interest
5.4%
Employees
2k
Rev per Employee
$1.3m
Show more

Is Neurocrine Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Neurocrine Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

29x Buy
85%
5x Hold
15%

Analyst Opinions

34 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

Buy
85%
Hold
15%

Financial data from Neurocrine Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2,510 2,510
18% 18%
100%
- Direct Costs 38 38
4% 4%
2%
2,472 2,472
19% 19%
98%
- Selling and Administrative Expenses 1,085 1,085
19% 19%
43%
- Research and Development Expense 888 888
41% 41%
35%
528 528
7% 7%
21%
- Depreciation and Amortization 29 29
15% 15%
1%
EBIT (Operating Income) EBIT 499 499
8% 8%
20%
Net Profit 348 348
3% 3%
14%

In millions USD.

Don't miss a Thing! We will send you all news about Neurocrine Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neurocrine Biosciences, Inc. Stock News

Neutral
Seeking Alpha
about 16 hours ago
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Cantor Global Healthcare Conference 2025 September 3, 2025 1:00 PM EDT Company Participants Matthew Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Presentation Joshua Schimmer Biotech Equity Research Analyst Now we're ready to get st...
Neutral
PRNewsWire
9 days ago
SAN DIEGO , Aug. 26, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at four investor conferences in September. Chief Financial Officer Matt Abernethy, Chief Commercial Officer Eric Benevich, and Vice-President of Investor Relations Todd Tushla will present at the Cantor Global Healthcare Conference 2025 at 1:00 p.m.
Neutral
PRNewsWire
29 days ago
SAN DIEGO , Aug. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Canaccord Genuity 45th Annual Growth Conference at 8:00 a.m. ET on Wednesday, August 13, 2025.
More Neurocrine Biosciences, Inc. News

Company Profile

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.

Head office United States
CEO Kyle Gano
Employees 1,800
Founded 1992
Website www.neurocrine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today